Latest / Vanguards of Healthcare by Bloomberg Intelligence
Natera’s Billion-Dollar R&D Bet on the Future of Cancer Testing
“Clinical data is the key to being successful in diagnostics,” Steve Chapman, CEO of Natera, tells Bloomberg Intelligence analyst Jonathan Palmer as he explains how an early bet on evidence helped turn a small genetic-testing company into a broad diagnostics platform. Chapman traces Signatera from a side project into a leading minimal residual disease (MRD) test and details Natera’s nearly $1 billion R&D investment to push into genome-based testing, early cancer detection and new indications. The conversation also explores the next layer of value from Natera’s platform…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.